ALTIMMUNE STOCK CRASH
Altimmune’s stock plummets over 60% as liver drug falls short in trialAltimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key ...
- Load More
Copyright © 2026 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights:
Times Syndication Service